This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
Daily dosing for 21 consecutive days
Daily dosing for 21 consecutive days
Daily dosing for 21 consecutive days
Alkermes Investigational Site
Chula Vista, California, United States
Changes in blood glucose concentrations
Differences will be compared among treatment groups
Time frame: 21 days
Changes in insulin concentrations
Differences will be compared among treatment groups
Time frame: 21 days
Incidence of treatment-emergent adverse events (AEs)
Time frame: 24 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.